Compare ZKH & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | ZVRA |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.8M | 472.9M |
| IPO Year | 2022 | 2015 |
| Metric | ZKH | ZVRA |
|---|---|---|
| Price | $3.14 | $10.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 94.2K | ★ 663.0K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $9.02 | $37.27 |
| Revenue Next Year | $10.41 | $53.42 |
| P/E Ratio | ★ N/A | $7.70 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $2.20 | $6.85 |
| 52 Week High | $3.90 | $13.16 |
| Indicator | ZKH | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 68.59 |
| Support Level | $3.08 | $10.69 |
| Resistance Level | $3.54 | $11.19 |
| Average True Range (ATR) | 0.15 | 0.39 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 75.68 | 91.29 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.